Overview
This clinical research study will test the safety and efficacy of the investigational medication MAU868, compared to a placebo, in patients who have had a kidney transplant who have active BK virus.
Eligibility
Inclusion Criteria:
- Be a male or female 18 years of age or older.
- Recipient of a kidney (or kidney-pancreas) transplant within the year prior to enrollment
- Documented BKV viremia based on local or central laboratory testing within 10 days
Exclusion Criteria:
- A BKV plasma viral load which has exceeded 10^3 copies/mL for >4 months.
- A BKV plasma viral load of 10^7 copies/mL.